EUVIMEDEUVIMED entdecken
Crossref

Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling

Hong-Beum Kim, Yong Sub Na, Seong-Hun Kim, Hee-Jeong Lee, Sang-Gon Park

Anticancer Research · 2026

DOI: 10.21873/anticanres.17935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hong-Beum Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Premedical Course, Chosun University School of Medicine, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Small Cell Lung Carcinoma, Proto-Oncogene Proteins c-akt, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic progress. Adenylate kinase 2 (AK2), a mitochondrial isoenzyme involved in nucleotide metabolism and apoptosis regulation, has been implicated in tumorigenesis, but its role in SCLC remains undefined. This study aimed to investigate the oncogenic function of AK2 in SCLC and its regulatory mechanism through the PI3K/AKT/mTOR signaling pathway. MATERIALS AND METHODS: AK2 expression was analyzed using the GSE60052 dataset and validated using western blotting in SCLC cell lines. Functional assays, including MTT, proliferation, colony formation, and phospho-kinase array profiling, were performed following siRNA-mediated AK2 knockdown in HCC-33 and H417 cells. Western blotting was used to confirm pathway alterations. In vivo tumorigenicity was assessed in xenograft models. RESULTS: AK2 was markedly up-regulated in SCLC tissues and cell lines. Silencing AK2 significantly inhibited proliferation and clonogenic growth of SCLC cells and reduced tumorigenicity in vivo. Phospho-kinase analysis and western blot validation demonstrated that AK2 knockdown altered phosphorylation of key components in the PI3K/AKT/mTOR pathway, including AKT and mTOR. CONCLUSION: AK2 acts as an oncogenic driver in SCLC, promoting tumor progression through PI3K/AKT/mTOR signaling. Targeting AK2 may represent a novel therapeutic strategy and predictive biomarker in SCLC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesSmall Cell Lung CarcinomaProto-Oncogene Proteins c-aktLung NeoplasmsPhosphatidylinositol 3-KinasesAdenylate KinaseHumansSignal TransductionAnimalsCell ProliferationCell Line, TumorMiceDisease ProgressionMaleFemaleGene Expression Regulation, NeoplasticMice, Nude

Stichwörter der Autor:innen

PI3K/AKT/mTOR signalingSmall cell lung canceradenylate kinase 2(AK2)tumor progression

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAdenylate KinaseMTOR protein, humanadenylate kinase 2

Autor:innen und Institutionen

  • Department of Premedical Course, Chosun University School of Medicine, Gwangju, Republic of Korea.
  • Department of Internal Medicine, Pulmonology, Chosun University Hospital, Gwangju, Republic of Korea.
  • Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea.
  • Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea sgpark@chosun.ac.kr.

Zitieren

APA

Kim, H. B., Na, Y. S., Kim, S. H., Lee, H. J., & Park, S. G. (2026). Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling. Anticancer Research. https://doi.org/10.21873/anticanres.17935

Vancouver

Kim HB, Na YS, Kim SH, Lee HJ, Park SG. Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling. Anticancer Research. 2026. doi:10.21873/anticanres.17935

BibTeX
@article{Kim2026,
  author = {Kim, Hong-Beum and Na, Yong Sub and Kim, Seong-Hun and Lee, Hee-Jeong and Park, Sang-Gon},
  title = {Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.17935}
}
Kostenlos starten →